CVS Health Corp. has asked a New York state court to dismiss the state’s antitrust lawsuit alleging that the pharmacy chain is forcing the state’s 340B covered entities to use its 340B third party administrator Wellpartner as a condition for letting the entities contract with CVS retail and specialty pharmacies to dispense 340B-purchased drugs. CVS’s motion argues the suit fails to state a claim under New York’s anti-trust laws.
CVS also alleged that the suit, filed in late July by New York State Attorney General Letitia James, ignores the benefits its third-party administrator (TPA) deal with Wellpartner achieves by maximizing 340B savings for covered entities, and points out that contract pharmacy competitors such as Walgreens have a similar TPA contract with 340B providers.
CVS Health Corp. has asked a New York state court to dismiss the state’s antitrust lawsuit alleging that the pharmacy chain is forcing the state’s 340B covered entities to use its 340B third party administrator Wellpartner as a condition for letting the entities contract with CVS retail and specialty pharmacies to dispense 340B-purchased drugs.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
